Deverra Therapeutics, Inc. is a clinical stage biotechnology company located in Seattle, Washington, developing allogeneic, off-the-shelf universal donor cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. 

The company has exclusive license to the proprietary Notch-mediated stem cell expansion and directed differentiation platform from the Fred Hutchinson Cancer Research Center based on more than 20 years of federally funded research and multiple clinical trials.

Our innovative and well-established platform can be used to generate a range of unmodified and modified (engineered) progenitor and immune cells to boost the patient’s blood and immune system to eliminate cancer and virally infected cells.

Deverra’s team includes pioneers who were the first to demonstrate clinical effectiveness using expanded stem cell therapies and  non-HLA matched, off-the-shelf universal donor cell therapies.

LEADING THE WAY

Colleen Delaney

Scientific Founder, Chief Scientific Officer and EVP, Research & Development

Michael Yurkowsky

President and Co-Founder

Erika von Euw 

VP, Discovery and Translational Research

OUR PARTNERS

Research Partners

Cord Blood Bank Partners